BDBM322521 5-[3-(4-phenyl-1H-imidazol-2-yl)chroman-6-yl]oxy-3,4-dihydro-1H-1,8-naphthyridin-2-one]::US10183939, Example 3::US10183939, Example 3A::US10183939, Example 3B::USRE49361, Example 3B

SMILES O=C1CCc2c(Oc3ccc4OCC(Cc4c3)c3nc(c[nH]3)-c3ccccc3)ccnc2N1

InChI Key InChIKey=CQHCHMVSWDLQFP-UHFFFAOYSA-N

Data  24 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 24 hits for monomerid = 322521   

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.40nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.5nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.600nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Jazz Pharmaceuticals Ireland

US Patent
LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:B-RAF, RAFV600E, and C-RAF: Compounds at a concentration of 3 mM are serially diluted (e.g. 10 μl, 90 μl of 100% dimethyl sulfoxide (DMSO))...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details
US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.40nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 1.5nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.600nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 0.800nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
Affinity DataIC50: 4nMAssay Description:To determine whether compounds bind to RAF kinases, they are tested in a competition binding assay. The Invitrogen LanthaScreen Eu binding assay invo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

LigandPNGBDBM322521(US10183939, Example 3 | US10183939, Example 3B | U...)
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent